Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Calcitonin-Salmon (Miacalcin) vs Linaclotide (Linzess)
An educational, source-based comparison of Calcitonin-Salmon (Miacalcin) and Linaclotide (Linzess) — how each peptide works, what it's researched for, and what to know before going deeper.
32-amino-acid peptide for osteoporosis and hypercalcemia.
Synthetic salmon calcitonin inhibits osteoclast-mediated bone resorption and promotes renal calcium excretion. Available as nasal spray or injection.
- Postmenopausal osteoporosis (>5 yrs postmenopause)
- Paget's disease
- Hypercalcemia
- • FDA-approved.
- • FDA cautions about possible malignancy signal with long-term use.
Guanylate cyclase-C agonist peptide for IBS-C and chronic constipation.
14-amino-acid peptide that activates intestinal guanylate cyclase-C, increasing cGMP and chloride/bicarbonate secretion into the gut lumen — accelerating transit and reducing visceral pain.
- IBS-C
- Chronic idiopathic constipation
- Functional constipation in children
- • FDA-approved.
- • Contraindicated in children <2 years; diarrhea common.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Calcitonin-Salmon (Miacalcin) | PROOF study | American Journal of Medicine | 2000 | Reduced vertebral fracture risk in postmenopausal osteoporosis. |
| Linaclotide (Linzess) | Linaclotide phase 3 trials | NEJM | 2011 | Improved abdominal pain and bowel function in IBS-C. |
Side-effect & safety grid
- FDA-approved.
- FDA cautions about possible malignancy signal with long-term use.
- FDA-approved.
- Contraindicated in children <2 years; diarrhea common.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Calcitonin-Salmon (Miacalcin) vs Linaclotide (Linzess) — Key differences
- Class: Calcitonin-Salmon (Miacalcin) is classified as Calcitonin · Bone Resorption, while Linaclotide (Linzess) is GC-C Agonist · Gastrointestinal.
- Primary research focus: Calcitonin-Salmon (Miacalcin) — postmenopausal osteoporosis (>5 yrs postmenopause); Linaclotide (Linzess) — ibs-c.
- Tag: FDA-Approved · Bone vs FDA-Approved · GI.